Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003)

Annals of the Rheumatic Diseases

Volumn 62, Issue SUPPL. 2, 2003, Pages 2-9

  Furst, D E ^a   Breedveld, F C ^b   Kalden, J R ^c   Smolen, J S ^d   Burmester, G R ^e   Dougados, M ^f   Emery, P ^g   Gibofsky, A ^h   Kavenaugh, A F ⁱ   Keystone, E C ^j   Klareskog, L ^k   Russell, A S ^l   Van De Putte, L B A ^m   Weisman, M H ⁿ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f Hopital Cochin ^*  (France)

^g UNIVERSITY OF LEEDS   (United Kingdom)

^h HOSPITAL FOR SPECIAL SURGERY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j MOUNT SINAI HOSPITAL   (Canada)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^l UNIVERSITY OF ALBERTA   (Canada)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; PROTEIN INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

APLASTIC ANEMIA; BACTERIAL ARTHRITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISEASE EXACERBATION; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; HUMAN; IMMUNE RESPONSE; INFECTION; INFECTION SENSITIVITY; INFLAMMATORY DISEASE; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; MYCOSIS; OPTIC NERVE DISEASE; OSTEOMYELITIS; PANCYTOPENIA; PRIORITY JOURNAL; REGISTER; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TUBERCULOSIS;

EID: 0142249766     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.suppl_2.ii2     Document Type: Conference Paper

References (101)

1. Van de Putte L, Atkins C, Malaise M, et al. Adalimumab monotherapy in the treatment of patients with severe active RA [abstract]. Arthritis Rheum 2002;46(suppl):
2. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000;59:1341-59.
3. Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003;48:218-26.
4. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
5. Kavanaugh AF. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998;24:593-614.
6. Jones RE, Moreland LW. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis 1999;48:1-4.
7. Harriman G, Harper LK, Schaible TF. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment. Ann Rheum Dis 1999;58(suppl I):161-4.
8. Garrison L, McDonnell ND. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58(suppl I):165-9.
9. Furst DE, Keystone E, Maini RN, Smolen JS. Recapitulation of the round-table discussion - assessing the role of anti-tumor necrosis factor therapy in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 1999;38(suppl 2):50-3.
10. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993;36:1681-90.
11. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1125-7.
12. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
13. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
14. Moreland LW, Margolies G, Heck LW Jr, Saway A, Blosch C, Hanna R, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996;23:1849-55.
15. Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999;57:945-66.
16. Furst D, Schiff M, Fleischmann R, et al. Safety and efficacy of adalimumab-given in combination with standard antirheumatic therapy [abstract]. Arthritis Rheum 2002;46(suppl);S572.
17. Cush JJ, Spiera R. Etanercept update on recent "dear doctor" safety letter [magazine article]. ACR Hotline 2002:12-5.
18. Combe B, Condreanu C, Frosco U, et al. Double-blind comparison of etanercept and sulphasalazine alone and combined in patients with active RA [abstract]. Arthritis Rheum 2002;46(suppl):S519.
19. Burmester G, Van de Putte L, Rau R, et al. Long tem efficacy and safety of adalimumab montherapy in patients with DMARD-refractory RA-results from a two year study [abstract]. Arthritis Rheum 2002;46(suppl):S537.
20. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
21. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
22. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002;359:1187-93.
23. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56.
24. Antoni C, Kavanaugh AF, Kirkham B, et al. The infliximab multinational trial of psoriatic arthritis [abstract]. Arthritis Rheum 2002;46(suppl):S381.
25. Baeten D, Demetter P, Kruithof E, et al. Effect of TNF alpha blockade on synovial histology in spondyloarthropathy [abstract]. Arthritis Rheum. 2000;43(suppl):S4040.
26. Brandt J, Kavanaugh AF, Listing J, et al. Six months results of a German double-blind placebo controlled phase III clinical trial in active ankylosing spondylitis [abstract]. Arthritis Rheum 2002;46(suppl):S429.
27. Brandt J, Haibel H, Reddig J, et al. Anti-TNF alpha treatment of patients with severe anklyosing spondylitis - a one year follow-up [abstract]. Arthritis Rheum. 2000;44(suppl):S403.
28. Weinblatt ME, Maier AI, Overman SS. Etanercept in Still's disease in adult [abstract]. Arthritis Rheum 2000;43(suppl)S391.
29. Huffstutter J, Sienknecht C. Resistant adult still's disease with infliximab - a report of two cases [abstract]. Arthritis Rheum 2002;46(suppl):S326.
30. Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab [abstract]. Arthritis Rheum. 2001;44(suppl):S118.
31. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001;358:295-6.
32. Rozenbaum M, Rosner I, Portnoy E. Remission of Behçet's syndrome with TNFα blocking treatment. Ann Rheum Dis 2002;61:283-284.
33. Melikoghu M, Fresko I, Mat C, et al. Etanercept is beneficial in controlling the mucocutaneous lesions of Behcet's syndrome [abstract]. Arthritis Rheum 2002;46(suppl):S206.
34. Sfikakis PP. Behcet's disease: a new target for anti-tumor necrosis factor treatment Ann Rheum Dis 2002;61(suppl II):ii51-3.
35. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum 2001;44:2371-5.
36. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
37. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT1 randomised trial. Lancet 2002;359:1541-9.
38. Khanna D, Liebling M, Louie J. Treatment of resistant sarcoid arthropathy with etanercept. J Rheumatol (in press).
39. Sweiss N, Ellman N, Cunan J, Utset T, et al. TNF-inhibitor as novel treatment for refractory sarcoidosis [abstract]. Arthritis Rheum 2002;46(suppl):S324.
40. Hengstman G, van den Hoogen F, ven Engelen B, et al. Anti-TNF blockade with infliximab (Remicade) in polymyositis and dermatomyositis [abstract]. Arthritis Rheum 2000;43(suppl):S193.
41. Miller M, Mendez E, Klein-Gitelman M, Pachman L. Use of etanercept in juvenile dermatomyositis [abstract]. Arthritis Rheum 2002;46(suppl):S306.
42. Saadeh C. Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy [abstract]. Arthritis Rheum 2000;43(suppl):S193.
43. Gottlieb A, Chadhari U, Mulcahy L, et al. Infliximab monotherapy is a remittive treatment for plague-type psoriasis [abstract]. Arthritis Rheum 2002;46(suppl):S161.
44. Ehresman G. Infliximab in the treatment of polychondritis [abstract]. Arthritis Rheum 2002;46(suppl):S160.
45. Ortiz-Santamaria V, Vals-Roc M, Sanmarti M, et al. Treatment of secondary amyloidosis with infliximab [abstract]. Arthritis Rheum 2002;46(suppl):S71.
46. Tomero E, Carmona L, Gonzalez I, et al. Infliximab in secondary amyloidosis complicating inflammatory arthropathies [abstract]. Arthritis Rheum 2002;46(suppl):S70.
47. Weiss J, Eberhard B, Gottlieb B, et al. Infliximab as a novel therapy for refractory Kawasaki's sisease [abstract]. Arthritis Rheum 2002;46(suppl):S310.
48. Athreya B, Doughty R, Kastner D, et al. Periodic fever syndrome in children [abstract]. Arthritis Rheum 2000;43 (suppl);S117.
49. Ellman MH, MacDonald PA, Hayes FA. Etanercept treatment for diffuse scleroderma: a pilot study [abstract]. Arthritis Rheum 2000;43(suppl):S392.
50. Tan A, Holdsworth J, Pease C, Emery P, McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003;62:373-4.
51. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
52. Bray VJ. The safety of infliximab infusion in clinical practice [abstract]. Arthritis Rheum 2001;44(suppl):S83.
53. Stone J, Uhlfelder M, Hellmann D, et al. Etanercept in Wegener's granulomatosis: a six-month open-label trial to evaluate safety [abstract]. Arthritis Rheum 2000;43(suppl):S404.
54. Genovese M, Bathon JM, Martin R, Fleischmann RM, Tesser JR, Schiff MH, et al. Enbrel (etanercept) vs methotrexate (MTX) in early rheumatoid arthritis (ERA trial): two-year follow-up. Arthritis Rheum 2002;46:1443-50.
55. Brocq O, Breiul V, Plubel Y, et al. Etanercept-infliximab switch in RA, 14 out of 131 patients treated with anti-TNFα. Presse Med 2002;31:1836-9.
56. Maksymowych WP, Mallon C, Spady B, Peerani R. Alberta Capital Health region studies in rheumatoid arthritis prospective observational inception cohort: efficacy, adverse events and withdrawal [abstract]. Arthritis Rheum 2002;44(suppl):S82.
57. Schiff M, Mease P, Weinblatt M, et al. Randomized controlled trial of 25mg vs. 50mg enbrel (etanercept) twice weekly in rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2000;43(suppl):S391.
58. Shergy WJ, Phillips Jr RM, Hunt RE, Hernandez J. Safety and efficacy of infliximab therapy after etanercept failure: a case series [abstract]. Arthritis Rheum. 2001;44(suppl):S81.
59. Van Vollenhoven RF, Gullstrom E, Brannemark S, Klareskog L. Dose escalation of infliximab in clinical practice. Data from the Stockholm TNF alpha registry [abstract]. Arthritis Rheum 2001;44(suppl):S82.
60. Wassermann MJ, Weber D, Bykerk V, Lee P, Keystone EC. Efficacy of infliximab (3 mg per kilogram) in a population of severe long-standing RA patients treated in a quaternary care center [abstract]. Arthritis Rheum 2001;44(suppl):S82.
61. Keystone E, Kavanaugh A, Sharp J, et al. Adalimumab, a fully human anti-TNF-alpha monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy [abstract]. Arthritis Rheum 2002;46(suppl):S205.
62. Antoni CE, Furst D, Manger B, Lichtenstein GR, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's diseaes or rheumatoid arthritis [abstract]. Arthritis Rheum 2001;44(suppl):S152.
63. Bingham S, Barcelos A, Buch M, et al. Induction of serological lupus in patients on leflunomide and infliximab [abstract]. Arthritis Rheum 2002;46(suppl):S168.
64. Christopher L, Wigley F. TNF-Alpha antagonists induce lupus-like syndrome in patients scleroderma and polyarthritis [abstract]. Arthritis Rheum 2002;46(suppl):S358.
65. De Rycke L, Damme N, Kruithof E, et al. Antinuclear antibody profile following infliximab treatment in RA and SpA [abstract]. Arthritis Rheum 2002;46(suppl):S128.
66. Wagner C, St Clair EW, Han C, et al. Effects of antibodies to infliximab on ACR response in patients with RA in the ATTRACT Study [abstract]. Arthritis Rheum 2002;46(suppl):S132.
67. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999;13(suppl 4):16-22.
68. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
69. Doran MF, Crowson CS, Pand GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
70. Elkayam O, Casp D, Paran D, Litinsky I, Rubins J. Effect of anti-TNF alpha therapies on the immunogenicity of pneumococcal vaccination in patients with rheumatic diseases [abstract]. Arthritis Rheum 2002;46(suppl):S340.
71. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003;48:319-24.
72. Khanna D, McMahon M, Spiegel J, Furst, D. Comparing TNF blocking agents. Drug Safety (submitted).
73. Singh G, Ramey D, Rausch PL, Schettler J. Serious infections in rheumatoid arthritis: relationship to immunosuppressive use [abstract]. Arthritis Rheum 1999;42(suppl):S242.
74. Baeten D, De Keyser F, Kruithof E, et al. Systematic review of the serious and atypical infections in spondyloarthropathy patients treated with anti-TNFx [abstract]. Arthritis Rheum 2002;46(suppl):S432.
75. Bargstrom L, Yocum D, Tesser J, et al. Coccidiomycosis (valley fever) occurring during infliximab therapy [abstract]. Arthritis Rheum 2002;46(suppl):S169.
76. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70.
77. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent. N Engl J Med 2001;345:1098-104.
78. Manadan A, Mohan A, Cote T, Siegel J, Sequeira W, Block J. Tuberculosis and etanercept treatment [abstract]. Arthritis Rheum 2002;46(suppl):S166.
79. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
80. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumour necrosis factor antagonist. Ann Intern Med 2003;138:807-11.
81. Peterson J, Wener M, Hsu Fea. Safety of TNF alpha antagonists in patients with rheumatoid arthritis and chronic hepatitis C [abstract]. Arthritis Rheum 2001;44(suppl):S78.
82. Prior P, Symmons DP, Hawkins CF, Scott DL, Brown R. Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 1984;43:128-31.
83. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978;31:691-6.
84. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-1.
85. Moreland LW. 24 week double-blind trial of etanercept and IL-1ra in RA. Symposium at ACR, 2002.
86. Furst DE, Cush J, Kaufmann S, Siegel J, Kurth R. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002;61(suppl II):ii62-3.
87. Anker SD, Coats AJ. How to recover from renaissance? The significance of the results of recover, renaissance, renewal and attach. Int J Cardiol 2002;86:123-30.
88. Olivieri I, Padula A, Ciancio G, Salvarani C, Niccoli L, Cantini F. Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis 2002;61:375-6.
89. Wagner AD, Andresen J, Jendro MC, Hulsemann JL, Zeidler H. Sustained Response to tumor necrosis factor x-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 2002;46:1965-8.
90. Breshnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domijan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
91. Jian Y, Genant HK, Watt I, Cobby M, Breshnihan B, Aitchison R, et al. A multicenter, double-blind, dose ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43:1001-9.
92. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt M, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Arthritis Rheum 2002;46:614-24.
93. Dayer J-M, Breshnihan B. Targeting interleukin-1 in the treatment of rheumatoid arthritis. Arthritis Rheum 2002;46:574-8.
94. Schiff M, van de Putte LB, Breedveld FC, Kupper H, Fischkoff S, et al. Rates of infection in adalimumab RA clinical trials. Ann Rheum Dis 2003;62(suppl I):abstr 184.
95. Cohen S, Nakelsky S, Mulani P, Badamgarav E, Harada A, Sokolskiy L, et al. The impact or anakinra therapy on patient centered outcomes in rheumatoid arthritis [abstract]. Arthritis Rheum 2001;44(suppl):S77(abstr 149).
96. Schiff MH, Bulpitt K, Weaver AA, Kazazi F, Joh T, Newmar R. Safety of combination therapy with anakinra and etanercept in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2001;44(suppl):S79(abstr 157).
97. Fleischman R, Tesser J, Schechtman J, Modaferri D, Poulakos J, Bennett R, et al. A safety trial of anakinra, recombinant il-1Ra, in a large, placebo controlled, heterogenous population of patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2001;44(suppl):S84(abstr 190).
98. Andrias R, Povaro, Rudge S, et al. Preliminary data from a study of kinert (anakinra) in children with juvenile RA [abstract]. Arthritis Rheum 2002;46(suppl):S215 (abstr 496).
99. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999;318:593-6.
100. Wolfe F, Pincus T, O'Dell J. Arthritis disease status in the clinic: which variables best predict change in therapy. J Rheumatol 2001;28:1712-17.
101. Braun J, Pham T, Sieper J, Davis J, van der Linden Sj, Dougados M, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.